000289300 001__ 289300
000289300 005__ 20240603153935.0
000289300 0247_ $$2doi$$a10.1158/1078-0432.CCR-23-4033
000289300 0247_ $$2pmid$$apmid:38573059
000289300 0247_ $$2ISSN$$a1078-0432
000289300 0247_ $$2ISSN$$a1557-3265
000289300 0247_ $$2altmetric$$aaltmetric:161541339
000289300 037__ $$aDKFZ-2024-00695
000289300 041__ $$aEnglish
000289300 082__ $$a610
000289300 1001_ $$00000-0001-7733-383X$$aHansford, Jordan R$$b0
000289300 245__ $$aUpdate on cancer predisposition syndromes and surveillance guidelines for childhood brain tumors.
000289300 260__ $$aPhiladelphia, Pa. [u.a.]$$bAACR$$c2024
000289300 3367_ $$2DRIVER$$aarticle
000289300 3367_ $$2DataCite$$aOutput Types/Journal article
000289300 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1717421922_4830$$xReview Article
000289300 3367_ $$2BibTeX$$aARTICLE
000289300 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289300 3367_ $$00$$2EndNote$$aJournal Article
000289300 500__ $$a2024 Jun 3;30(11):2342-2350
000289300 520__ $$aTumors of the central nervous system (CNS) comprise the second most common group of neoplasms in childhood. The incidence of germline predisposition among children with brain tumors continues to grow as our knowledge on disease aetiology increases. Some children with brain tumors may present with non-malignant phenotypic features of specific syndromes (e.g. nevoid basal cell carcinoma syndrome, neurofibromatosis type 1 and type 2, DICER1 syndrome, and constitutional mismatch repair deficiency), while others may present with a strong family history of cancer (e.g. Li-Fraumeni syndrome), or with a rare tumor commonly found in the context of germline predisposition (e.g. rhabdoid tumor predisposition syndrome). Approximately 50% of patients with a brain tumor may be the first in a family identified to have a predisposition. The past decade has witnessed a rapid expansion in our molecular understanding of CNS tumors. A significant proportion of CNS tumors are now well characterized and known to harbor specific genetic changes that can be found in the germline. Additional novel predisposition syndromes are also being described. Identification of these germline syndromes in individual patients has not only enabled cascade testing of family members and early tumor surveillance but increasingly has also impacted cancer management in those patients. Therefore, the AACR Cancer Predisposition Working Group chose to highlight these advances in CNS tumor predisposition and summarize and/or generate surveillance recommendations for established and more recently emerging pediatric brain tumor predisposition syndromes.
000289300 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000289300 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289300 7001_ $$00000-0001-7653-9529$$aDas, Anirban$$b1
000289300 7001_ $$00000-0001-7392-6515$$aMcGee, Rose B$$b2
000289300 7001_ $$00000-0001-5394-8194$$aNakano, Yoshiko$$b3
000289300 7001_ $$00000-0002-9475-0077$$aBrzezinski, Jack$$b4
000289300 7001_ $$00000-0003-2017-0245$$aScollon, Sarah R$$b5
000289300 7001_ $$00000-0001-8333-0758$$aRednam, Surya P$$b6
000289300 7001_ $$00000-0003-2543-8378$$aSchienda, Jaclyn$$b7
000289300 7001_ $$00000-0002-6097-6457$$aMichaeli, Orli$$b8
000289300 7001_ $$00000-0002-9560-0652$$aKim, Sun Young$$b9
000289300 7001_ $$00000-0001-6159-5472$$aGreer, Mary-Louise C$$b10
000289300 7001_ $$00000-0002-6501-4150$$aWeksberg, Rosanna$$b11
000289300 7001_ $$00000-0001-8193-1488$$aStewart, Douglas R$$b12
000289300 7001_ $$00000-0001-7427-4651$$aFoulkes, William D$$b13
000289300 7001_ $$00000-0002-5019-2683$$aTabori, Uri$$b14
000289300 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b15$$udkfz
000289300 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b16$$udkfz
000289300 7001_ $$00000-0002-6721-122X$$aBrodeur, Garrett M$$b17
000289300 7001_ $$00000-0002-2852-7387$$aKamihara, Junne$$b18
000289300 773__ $$0PERI:(DE-600)2036787-9$$a10.1158/1078-0432.CCR-23-4033$$n11$$p2342-2350$$tClinical cancer research$$v30$$x1078-0432$$y2024
000289300 909CO $$ooai:inrepo02.dkfz.de:289300$$pVDB
000289300 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000289300 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000289300 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000289300 9141_ $$y2024
000289300 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000289300 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000289300 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-25
000289300 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000289300 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000289300 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-25
000289300 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000289300 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000289300 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CANCER RES : 2022$$d2023-08-25
000289300 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000289300 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bCLIN CANCER RES : 2022$$d2023-08-25
000289300 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000289300 980__ $$ajournal
000289300 980__ $$aVDB
000289300 980__ $$aI:(DE-He78)B062-20160331
000289300 980__ $$aUNRESTRICTED